Second-line intraperitoneal (i.p.) therapy has been demonstrated to result in surgically defined complete responses (S-CR) in 25%–40% of patients with small-volume residual ovarian cancer (microscopic disease or largest tumor mass <1 cm="" in="" diameter).="" to="" evaluate="" the="" influence="" of="" the="" surgical="" finding="" of="" diffuse="" peritoneal="" carcinomatosis="" on="" the="" s-cr="" rate="" to="" salvage="" i.p.="" therapy="" in="" this="" patient="" population,="" we="" retrospectively="" reviewed="" the="" operative="" reports="" of="" 70="" patients="" with="" small-volume="" residual="" ovarian="" cancer="" treated="" on="" one="" of="" three="" phase-2="" second-line="" i.p.="" trials="" at="" the="" memorial="" sloan-kettering="" cancer="" center.="" of="" the="" 11="" patients="" with="" diffuse="" carcinomatosis,="" none="" achieved="" a="" s-cr="" compared="" to="" a="" s-cr="" rate="" of="" 37%="" (22/59)="" in="" patients="" without="" this="" surgical="" finding="">²=6.0;P<0.025). however,="" of="" the="" 7="" patients="" with="" diffuse="" carcinomatosis="" treated="" on="" a="" cisplatin-based="" i.p.="" program,="" the="" only="" 2="" who="" had="" previously="" responded="" to="" systemic="" platinum="" also="" experienced="" a="" response="" (partial)="" to="" the="" i.p.="" cisplatin="" regimen.="" in="" conclusion,="" while="" the="" surgical="" finding="" of="" diffuse="" peritoneal="" carcinomatosis="" indicates="" a="" poor="" prognosis="" in="" patients="" with="" small-volume="" residual="" ovarian="" cancer="" for="" response="" to="" i.p.="" chemotherapy,="" patients="" in="" this="" clinical="" setting="" with="" prior="" evidence="" of="" platinum="" sensitivity="" may="" experience="" some="" benefit="" from="" an="" i.p.="" cisplatin-based="" treatment="">